WISCONSIN NATIONAL PRIMATE RESEARCH CENTER SUPPORT

威斯康星州国家灵长类研究中心支持

基本信息

  • 批准号:
    8173147
  • 负责人:
  • 金额:
    $ 5.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-01 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To understand the immunological and genetic basis of control of AIDS virus replication to help inform vaccine design. As in HIV-infected humans, a limited number of macaques, called "elite controllers (ECs)," spontaneously and effectively control SIV replication. Recently investigators in the UW-Madison/WNPRC AIDS Vaccine Research Lab identified sixteen ECs in a cohort of 196 Indian rhesus macaques. Genotyping for MHC class I alleles revealed that fourteen of these sixteen ECs expressed either Mamu-B*17 or Mamu-B*08, which appear to be the macaque functional equivalents of, in humans, HLA-B57 and HLA-B27, respectively. However, the monitoring and sampling of these animals, which were typically identified in the course of experiments run by different investigators, has not been consistent. Moreover, due to financial constraints, animals often must be euthanized at the end of specific studies. We plan to establish a sample bank, database, and to house existing and future EC macaques at the WNPRC. Making these unique resources available to the community of investigators working on SIV would be an extremely valuable service to the field. One of the biggest obstacles for HIV vaccine development is the lack of a clear understanding of the immune correlates for protection. Therefore, attempts to understand the potential mechanisms underlying apparent clinical protection in certain rare individuals (both human and macaque) who naturally exhibit protection without vaccination are highly significant. Studying elite controllers (ECs) of HIV replication is complicated by the fact that additional variables come into play, such as viral heterogeneity and the inability to know the source and timing of the infection. In contrast, nonhuman primate model studies allow uniformity of the viral inoculum by employing a single molecularly cloned virus.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 目的:了解控制艾滋病病毒复制的免疫学和遗传学基础,为疫苗设计提供依据。 与感染HIV的人类一样,有限数量的猕猴(称为“精英控制者(EC)”)自发有效地控制SIV复制。最近,UW-Madison/WNPRC艾滋病疫苗研究实验室的研究人员在一组196只印度恒河猴中发现了16个EC。MHC I类等位基因的基因分型显示,这16个EC中有14个表达Mamu-B*17或Mamu-B*08,它们似乎分别是猕猴在人类中HLA-B57和HLA-B27的功能等同物。然而,对这些动物的监测和取样并不一致,这些动物通常是在不同研究人员进行的实验过程中确定的。此外,由于财政限制,动物往往必须在特定研究结束时安乐死。我们计划建立一个样本库,数据库,并容纳现有的和未来的EC猕猴在WNPRC。将这些独特的资源提供给从事SIV研究的调查人员社区,将是对该领域的一项极其宝贵的服务。艾滋病毒疫苗开发的最大障碍之一是缺乏对保护免疫相关性的明确理解。因此,尝试了解某些在未接种疫苗的情况下自然表现出保护作用的罕见个体(人类和猕猴)明显临床保护的潜在机制非常重要。研究HIV复制的精英控制者(EC)是复杂的,因为额外的变量起作用,如病毒的异质性和无法知道感染的来源和时间。相比之下,非人灵长类动物模型研究允许通过采用单分子克隆病毒的病毒接种物的均匀性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONNA M PAULNOCK其他文献

DONNA M PAULNOCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONNA M PAULNOCK', 18)}}的其他基金

DIRECTOR'S OFFICE
董事办公室
  • 批准号:
    8173063
  • 财政年份:
    2010
  • 资助金额:
    $ 5.16万
  • 项目类别:
Modulation of innate immunity by microbial factors
微生物因素对先天免疫的调节
  • 批准号:
    6463236
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
MACROPHAGE ACTIVATION IN AFRICAN TRYPANOSOMIASIS
非洲锥虫病中的巨噬细胞激活
  • 批准号:
    6434265
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
MACROPHAGE ACTIVATION IN AFRICAN TRYPANOSOMIASIS
非洲锥虫病的巨噬细胞激活
  • 批准号:
    6621422
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
MACROPHAGE ACTIVATION IN AFRICAN TRYPANOSOMIASIS
非洲锥虫病的巨噬细胞激活
  • 批准号:
    6698013
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
MACROPHAGE ACTIVATION IN AFRICAN TRYPANOSOMIASIS
非洲锥虫病的巨噬细胞激活
  • 批准号:
    6838220
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
Modulation of innate immunity by microbial factors
微生物因素对先天免疫的调节
  • 批准号:
    6888539
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
Modulation of innate immunity by microbial factors
微生物因素对先天免疫的调节
  • 批准号:
    7067148
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
MACROPHAGE ACTIVATION IN AFRICAN TRYPANOSOMIASIS
非洲锥虫病中的巨噬细胞激活
  • 批准号:
    7013654
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:
Modulation of innate immunity by microbial factors
微生物因素对先天免疫的调节
  • 批准号:
    6746890
  • 财政年份:
    2002
  • 资助金额:
    $ 5.16万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 5.16万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 5.16万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 5.16万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 5.16万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 5.16万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 5.16万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 5.16万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 5.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 5.16万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 5.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了